...
首页> 外文期刊>The Journal of Infectious Diseases >Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy.
【24h】

Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy.

机译:HIV感染患者对抗逆转录病毒疗法的病毒学和免疫学反应不一致的临床结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: A subgroup of human immunodeficiency virus type 1 (HIV-1)-infected patients with severe immunodeficiency show persistently low CD4+ cell counts despite sustained viral suppression. It is unclear whether this immuno-virological discordance translates into an increased risk for clinical events. METHODS: Data analysis from a large multicenter cohort incorporating 14,433 HIV-1-infected patients in Germany. Treatment-naive patients beginning antiretroviral therapy (ART) with CD4+ cell counts <200 cells/muL who achieved complete and sustained viral suppression <50 copies/mL (n = 1318) were stratified according to the duration of immuno-virological discordance (failure to achieve a CD4+ cell count >/=200 cells/muL). Groups were compared by descriptive and Poisson statistics. The time-varying discordance status was analyzed in a multivariable Cox model. RESULTS: During a total of 5038 person years of follow-up, 42 new AIDS events occurred. The incidence rate of new AIDS events was highest in the initial 6 months of complete viral suppression (immuno-virological discordance group, 55.06; 95% confidence interval [CI], 30.82-90.82; and immune responder group, 24.54; 95% CI, 10.59-48.35) and decreased significantly by 65% per year in patients with immuno-virological discordance (incidence risk ratio, 0.35; 95% CI, 0.14-0.92; P = .03). Immuno-virological discordance and prior AIDS diagnosis were independently associated with new AIDS events (hazard ratio, 3.10; 95% CI, 1.09-8.82; P = .03). CONCLUSION: Compared with immune responders, patients with immuno-virological discordance seem to remain at increased risk for AIDS. Absolute risk is greatly reduced after the first 6 months of complete viral suppression.
机译:背景:严重免疫缺陷的人类免疫缺陷病毒1型(HIV-1)感染患者亚组显示,尽管持续抑制病毒,但CD4 +细胞计数持续降低。目前尚不清楚这种免疫-病毒学矛盾是否会导致临床事件的风险增加。方法:来自德国一个大型多中心队列的数据分析,纳入了14433名HIV-1感染患者。初次接受抗逆转录病毒疗法(ART),CD4 +细胞计数<200细胞/μL,达到完全且持续的病毒抑制<50拷贝/ mL(n = 1318)的未治疗患者根据免疫-病毒学不一致的持续时间进行分层(失败至达到CD4 +细胞计数> / = 200细胞/μL)。通过描述性和泊松统计比较各组。在多变量Cox模型中分析了时变不一致状态。结果:在总共5038人年的随访期间,发生了42例新的艾滋病事件。在完全病毒抑制的最初6个月中,新的AIDS事件的发生率最高(免疫-病毒不一致组为55.06; 95%置信区间[CI]为30.82-90.82;免疫应答组为24.54; 95%CI为(10.59-48.35),且免疫-病毒学不一致的患者每年显着下降65%(发生风险比,0.35; 95%CI,0.14-0.92; P = .03)。免疫-病毒学不一致和先前的艾滋病诊断与新的艾滋病事件独立相关(危险比,3.10; 95%CI,1.09-8.82; P = .03)。结论:与免疫应答者相比,免疫-病毒学不一致的患者似乎仍增加了患艾滋病的风险。完全抑制病毒后的头6个月,绝对风险会大大降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号